Print Page | Close Window

Corporate Profile

AtriCure is a medical device company providing innovative solutions designed to decrease the global Afib epidemic.

Stock Quote

ATRC (Common)
PriceChange% ChangeVolume
$35.45 + 0.200.57%177,837
Previous CloseToday's OpenIntraday HighIntraday Low
$35.25$35.11$35.50$34.47
Exchange: NASDAQ (US Dollar)
09/24/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Reports

Date
09/21/18
Download Documentation Investor Presentation
08/01/18
Download Documentation Q2 2018 Earnings Call Transcript
06/26/18
Download Documentation Analyst Meeting Transcript

All Recent News

DateTitle 
08/28/18AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial
Landmark study is the first prospective, randomized study comparing the Convergent approach to endocardial catheter ablation in persistent and long-standing persistent atrial fibrillation patients MASON, Ohio--(BUSINESS WIRE)--Aug. 28, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has completed enrollment of the full cohor... 
Printer Friendly Version
08/21/18AtriCure to Present at the Morgan Stanley Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Aug. 21, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt Hotel in New York on Friday, September 14, 2018. Management is scheduled to present at 1:00 p.m. Eastern Time. A live audio webcast of the presentation... 
Printer Friendly Version
08/01/18AtriCure Reports Second Quarter 2018 Financial Results
Updates 2018 Financial Outlook Worldwide revenue of $51.8 million – an increase of 14.5% year over year U.S. revenue of $40.8 million – an increase of 14.9% year over year International revenue of $11.0 million – an increase of 13.1% year over year Positive adjusted EBITDA of $0.8 million MASON, Ohio--(BUSINESS WIRE)--Aug. 1, 2018-- AtriCure, Inc.... 
Printer Friendly Version
07/16/18AtriCure to Present at the Canaccord Genuity 38th Annual Growth Conference
MASON, Ohio--(BUSINESS WIRE)--Jul. 16, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Canaccord Genuity 38th Annual Growth Conference at the Intercontinental Hotel in Boston on Thursday, August 9, 2018. Management is scheduled to present at 12:00 p.m. Eastern Time. A live audio webcast of t... 
Printer Friendly Version
  More News >>

National Recent News

DateTitle 
08/28/18AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial
Landmark study is the first prospective, randomized study comparing the Convergent approach to endocardial catheter ablation in persistent and long-standing persistent atrial fibrillation patients MASON, Ohio--(BUSINESS WIRE)--Aug. 28, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has completed enrollment of the full cohor... 
Printer Friendly Version
08/21/18AtriCure to Present at the Morgan Stanley Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Aug. 21, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt Hotel in New York on Friday, September 14, 2018. Management is scheduled to present at 1:00 p.m. Eastern Time. A live audio webcast of the presentation... 
Printer Friendly Version
08/01/18AtriCure Reports Second Quarter 2018 Financial Results
Updates 2018 Financial Outlook Worldwide revenue of $51.8 million – an increase of 14.5% year over year U.S. revenue of $40.8 million – an increase of 14.9% year over year International revenue of $11.0 million – an increase of 13.1% year over year Positive adjusted EBITDA of $0.8 million MASON, Ohio--(BUSINESS WIRE)--Aug. 1, 2018-- AtriCure, Inc.... 
Printer Friendly Version
07/16/18AtriCure to Present at the Canaccord Genuity 38th Annual Growth Conference
MASON, Ohio--(BUSINESS WIRE)--Jul. 16, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Canaccord Genuity 38th Annual Growth Conference at the Intercontinental Hotel in Boston on Thursday, August 9, 2018. Management is scheduled to present at 12:00 p.m. Eastern Time. A live audio webcast of t... 
Printer Friendly Version
  More National News >>

International Recent News

DateTitle 
08/28/18AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial
Landmark study is the first prospective, randomized study comparing the Convergent approach to endocardial catheter ablation in persistent and long-standing persistent atrial fibrillation patients MASON, Ohio--(BUSINESS WIRE)--Aug. 28, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has completed enrollment of the full cohor... 
Printer Friendly Version
06/05/18AtriCure and Baheal Group Establish Partnership and China Distribution Agreement
Baheal will serve as the exclusive distribution partner for AtriCure products across China MASON, Ohio--(BUSINESS WIRE)--Jun. 5, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes... 
Printer Friendly Version
04/25/17AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
AtriClip is the most widely used device globally for left atrial appendage management MASON, Ohio--(BUSINESS WIRE)--Apr. 25, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has sold more than 100,000 AtriClip® Left Atrial Appendage Exclusion System devices worldwide, which makes it the most widely used of all d... 
Printer Friendly Version
03/14/17AtriCure Names National Principal Investigator for the CONVERGE IDE Clinical Trial
MASON, Ohio--(BUSINESS WIRE)--Mar. 14, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has named Dr. David B. DeLurgio as the national principal investigator (PI) for the CONVERGE IDE clinical trial. Dr. DeLurgio is a cardiac electrophysiologist at Emory Healthcare in Atlanta, GA. He is Director of Electrophysiology... 
Printer Friendly Version
  More International News >>

Company Calendar

There are currently no events scheduled.
  More Events >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.